Eli Lilly's announcement of Zepbound's price cut aims to reclaim market share from counterfeit weight-loss drugs. With prices slashed to $399-$549, easier access to treatment is expected.
Lilly's press release emphasized the benefits of the new single-dose vials, stating, 'These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option.'
The shift from pre-filled injector pens to vials is seen as a strategic move to increase availability, with experts noting that vials could help reduce shortages that patients have faced.
By introducing affordability into the mix, Eli Lilly is confronting the growing prevalence of counterfeit weight-loss products, thus ensuring that legitimate patients have better access to quality medications.
Collection
[
|
...
]